CATX News & Events

Perspective Therapeutics announced that the first patients were dosed with [212Pb]VMT-alpha-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively. The first patient was treated with [212Pb]VMT-alpha-NET in a fourth cohort of the company's ongoing Phase 1/2a clinical trial of [212Pb]VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors, or NETs. The design of this dosing regimen will help determine whether front-loading could change response kinetics and further improve response rate and tolerability at the same cumulative administered dose. Additionally, the first patient was treated with [212Pb]PSV359 in a third cohort of the company's Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha. The company is conducting a multi-center, open-label, dose-escalation, dose-expansion study of [212Pb]VMT-alpha-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies.

Reports Q1 revenue $76,000, consensus $137,180. "The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position," said Thijs Spoor, Perspective's CEO. "Our focus on engineering the alpha advantage across every part of the radiopharmaceutical value chain - from the radioisotope to optimized structural chemistry, theranostic processes, and regional manufacturing - differentiates Perspective, and we look forward to providing clinical and manufacturing updates throughout 2026."

Perspective Therapeutics announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2, or SSTR2, expressing neuroendocrine tumors, or NETs, as part of a poster presentation at the American Association for Cancer Research, or AACR, Annual Meeting 2026. [212Pb]VMT-alpha-NET is potentially the first-in-class 212Pb-radiopharmaceutical therapy targeting SSTR2. Interim results with a data cut-off date of March 4, 2026 formed the basis of the AACR update. The presentation includes safety data from 64 patients across three dose cohorts who have received at least one treatment of [212Pb]VMT-alpha-NET, and efficacy analysis from two patients in Cohort 1 and 23 patients in Cohort 2. Efficacy analysis with earlier data cut-off dates for the same patients were previously presented at the 2026 ASCO Gastrointestinal Cancers Symposium in January 2026 and the European Society for Medical Oncology Congress 2025 in October 2025. As of the data cut-off date of March 4, 2026: Safety findings based on 64 patients who received at least one treatment: The 64 patients in this safety analysis comprised two patients in Cohort 1, 46 patients in Cohort 2, and 16 patients in Cohort 3; There were no reports of dose limiting toxicities, treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression; Grade 3 or higher treatment-emergent adverse events were reported in 23 patients or 36%. One of these patients, who was enrolled in Cohort 3, experienced a transient lymphocyte count decrease on the cusp of Grades 3 and 4. This event was subsequently determined by the site to be a Grade 3 event. This event was transient and resolved without medical intervention. The patient completed the full course of [212Pb]VMT-alpha-NET treatment of four treatments without interruption and remains on study. No further Grade 4 events have occurred in this patient or in other patients in the study. There were no Grade 5 events.